Bone Marrow Mesenchymal Stem Cells, Fresh
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into the cells of the connective tissue in vitro, such as chondrocytes (cartilage), osteoblasts (bone) and adipocytes (fat). Although little is known of the phenotypic characteristics of MSCs in vivo, MSCs in culture are defined by the expression of CD73, CD90, and CD105 and the lack of CD11b, CD19, CD34, CD45, and HLA-DR. Cultured MSCs have shown promising applications in cell-based therapeutic strategies for specific tissues and cancer research.
Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies. By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.
Description
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into the cells of the connective tissue in vitro, such as chondrocytes (cartilage), osteoblasts (bone) and adipocytes (fat). Although little is known of the phenotypic characteristics of MSCs in vivo, MSCs in culture are defined by the expression of CD73, CD90, and CD105 and the lack of CD11b, CD19, CD34, CD45, and HLA-DR. Cultured MSCs have shown promising applications in cell-based therapeutic strategies for specific tissues and cancer research.
Bone marrow mononuclear cells (MNCs) are separated from whole bone marrow by a density gradient centrifugation protocol. MNCs are cultured for 9-14 days in a medium that promotes MSCs. After culture, adherent cells are checked for >90% expression of CD73, CD90, and CD105 and <5% expression of CD14, CD34, and CD45 by flow cytometry.
Please request for cells to be cultured in animal component free (ACF) and serum-free medium.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
Additional information
| Fill Volume | Custom, 0,75 million/vial, Min 10 billion TNCs, Min 20 billion TNCs/bag, 0.2 million/vial, 0.25 billion TNCs, 0.3 million/vial, 0.5 million/vial, 0.5 billion TNCs, 1 million/vial, 1 billion TNCs, 1.5 million/vial, 2 million/vial, 2.5 million/vial, 2.5 billion TNCs, 4.5mL, 5 million/vial, 5mL, 5 billion TNCs, 10 million/vial, 10mL, 10 billion TNCs, 15 million/vial, 15mL, 20 million/vial, 20 billion TNCs/bag, 20mL, 25mL, 25 million/vial, 30 million/vial, 30mL, 35mL, 40 million/vial, 40mL, 45mL, 50 million/vial, 50mL, 60mL, 70mL, 80mL, 80-100mL, 90mL, 100mL, 100 million/vial, 110mL, 120mL, 130mL, 140mL, 150mL, 150 million/vial, 160mL, 170mL, 180mL, 190mL, 200 million/vial, 200mL, 250mL, 300 million/vial, 450mL, 500mL |
|---|---|
| Anticoagulant | |
| Format | |
| Grade | |
| Species | |
| Cell and Tissue Source | |
| Disease State | |
| Donor Attributes |
Related products
-
Bone Marrow CD105+ Cells, Frozen
Select options This product has multiple variants. The options may be chosen on the product page -
Bone Marrow CD34+ Stem/Progenitor Cells, Fresh
Select options This product has multiple variants. The options may be chosen on the product page -
Whole Blood, Fresh, EDTA
Select options This product has multiple variants. The options may be chosen on the product page -
Peripheral Blood CD8+CD45RA+ Naïve Cytotoxic T Cells, Frozen
Select options This product has multiple variants. The options may be chosen on the product page